Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Relmada Therapeutics, Inc. (RLMD) had Return on Equity of -66.33% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-57.39M |
|
-- |
|
-- |
|
$59.10M |
|
$-59.10M |
|
$1.72M |
|
$-57.39M |
|
$-57.70M |
|
$-57.39M |
|
$-57.39M |
|
$-57.39M |
|
$-57.70M |
|
$-59.10M |
|
$-59.10M |
|
39.48M |
|
39.48M |
|
$-1.45 |
|
$-1.45 |
|
| Balance Sheet Financials | |
$93.98M |
|
-- |
|
$0.02M |
|
$94.00M |
|
$6.43M |
|
-- |
|
$1.06M |
|
$7.49M |
|
$86.51M |
|
$86.51M |
|
$86.51M |
|
73.33M |
|
| Cash Flow Statement Financials | |
$-45.79M |
|
$-48.14M |
|
$93.56M |
|
$3.86M |
|
$3.50M |
|
$-0.36M |
|
$14.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.62 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-45.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-66.33% |
-66.33% |
|
-61.05% |
|
-66.33% |
|
$1.18 |
|
$-1.16 |
|
$-1.16 |
|